黑料网

Heart disease is one of the major complications associated with diabetes, however some of the first line treatments used to reduce a person鈥檚 risk of heart disease, don鈥檛 work as well in people with diabetes.

This problem is a major focus of research being conducted by Dr Brian Drew and his colleagues at the Baker Heart and Diabetes Institute and supported by the 黑料网 Research Trust.

Diabetes, Dr Drew says, often leads to an increase in 鈥榖ad鈥� cholesterol levels which contributes to the risk for heart disease in these people.

鈥淭he primary drugs used to lower cholesterol levels and reduce cardiovascular risk are statins. These drugs are generally effective in people who don鈥檛 have diabetes, but they are far less effective in people with diabetes,鈥� he says.

鈥淭his is a problem because people with diabetes are three to four times more likely to develop cardiovascular disease than people without diabetes.

鈥淲hat we鈥檙e working towards is a new drug target that would be effective in reducing bad cholesterol levels in people with diabetes.鈥�

Using high tech genetic screening, Dr Drew鈥檚 team has identified a protein which they call DDL1, which could play a role in regulating cholesterol levels differently to the way way current medications such as statins, work.

鈥淲e want to understand if this protein, DDL1, can alter cholesterol levels and we will be testing this in preclinical models,鈥� he says.

鈥淚t鈥檚 never been associated with lowering cholesterol levels before so we are breaking new ground.

鈥淲e hope that any new therapy could also work for people who experience some of the major side effects of statins like muscle soreness.鈥�